Search Results - nicholas+restifo

11 Results

Sort By:

Methods for Producing Stem Cell-Like Memory T Cells for Use in T Cell-Based Immunotherapies

Abstract: T cells currently employed for T cell-based immunotherapies are often senescent, terminally differentiated cells with poor proliferative and survival capacity. Recently, however, scientists at the National Cancer Institute (NCI) identified and characterized a new human memory T cell population with stem cell-like properties. Since these T...

Published: 4/17/2024 | Inventor(s): Luca Gattinoni, Nicholas Restifo, Mario Roederer, Enrico Lugli

Keywords(s): anti-tumor activity, CANCER, Gattinoni, GSK-3beta, Immunotherapy, Infection, Stem Cell, T cell, WNT

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, Application > Therapeutics

Methods of Producing Thymic Emigrants from Induced Pluripotent Stem Cells

Abstract: Hematopoietic and pluripotent stem cells can be differentiated into T cells with potential clinical utility. Current approaches for in vitro T cell production rely on Notch signaling and artificial mimicry of thymic selection. However, these approaches result in unconventional or phenotypically aberrant T cells; which may lead to unpredictable...

Published: 4/8/2024 | Inventor(s): Raul Sakoda, Nicholas Klemen, Nicholas Restifo

Keywords(s): DIFFERENTIATION, Induced Pluripotent Stem Cells, IPSCS, RESEARCH MATERIAL, Restifo, T Cells, Thymic Environment, Tool

Category(s): TherapeuticArea > Infectious Disease, Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Efficient Methods to Prepare Hematopoietic Progenitor Cells in vitro for Therapeutic Use

Abstract: Hematopoietic progenitor cells (HPC) are multi-potent hematopoietic lineage cells that can differentiate into any type of blood cell, including but not limited to erythrocytes, T cells, B cells, and natural killer cells. As such, they have high therapeutic potential in the fields of regenerative medicine and cancer immunotherapy, especially...

Published: 4/8/2024 | Inventor(s): Raul Sakoda, Nicholas Restifo, Meghan Good, Naritaka Tamaoki

Keywords(s): 3D Culture, BIOREACTOR, Hematopoietic Progenitor Cells, hiPSC, hMSC, HPC, Human Mesenchymal Stem Cells, Immunotherapy, Induced Pluripotent Stem Cells, iPSC, Vizcardo

Category(s): TherapeuticArea > Immunology, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing

High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes

Abstract: One form of adoptive T cell therapy (ACT) consists of harvesting tumor infiltrating lymphocytes (TIL), screening and isolating TIL which display tumor antigen-specific T-cell receptors (TCR), expanding the isolated T cells in vitro, and reinfusing them into the patient for treatment. While highly active in the treatment of certain cancers...

Published: 4/8/2024 | Inventor(s): Raul Sakoda, S M Rafiqul Islam, Naritaka Tamaoki, Takuya Maeda, Nicholas Restifo

Keywords(s): act, adoptive cell therapy, ANTIGEN-SPECIFIC, Cancer Targets, Immunotherapy, Induced Pluripotent Stem Cells, iPSC, Restifo, Rosenberg, T Cell Receptors, TCR, TIL, Tumor Infiltrated Lymphocytes

Category(s): TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics, Collaboration Sought > Licensing

Methods of Producing T-cell Populations Using P38 MAPK Inhibitors

Abstract: Adoptive cell therapy (ACT) uses cancer reactive T-cells to effectively treat patients. However, several obstacles inhibit the successful use of ACT for cancer treatment. Current approaches for the expansion of T-cells may produce T-cells with a terminally differentiated phenotype that is associated with diminished anti-tumor activity and...

Published: 4/8/2024 | Inventor(s): Nicholas Restifo, Shashankkumar Patel

Keywords(s): Immunotherapy. Restifo, inhibitor, Mapk, P38, T-CELLS

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

In vitro Generation of an Autologous Thymic Organoid from Human Pluripotent Stem Cells

Abstract: The thymus is an integral part of the adaptive immune system as it generates T cells. Its function diminishes rapidly as the body ages, leading to a compromise of the immune system in the elderly. Reconstitution of adaptive immunity through mass production of different T cell types is therefore a therapeutic need in immunocompromised populations....

Published: 4/8/2024 | Inventor(s): Raul Sakoda, Nicholas Restifo

Keywords(s): Aging, IMMUNOCOMPROMISED, Immunotherapy, Natural Killer T Cells, NKT, Organogenesis, Organoid, Pluripotent Stem Cells, T Cells, THYMUS, Vizcardo

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Licensing

Gene-based Diagnostic Predicts Patient Response to Cancer Immunotherapy

Abstract: Immunotherapy is a promising method of treating cancer that leverages the immune system to promote tumor rejection. However, certain somatic mutations in cancer cells confer resistance to T cell-mediated cytolysis. To improve the effectiveness of immunotherapies for cancer, there exists a need to prospectively identify patients who are most...

Published: 9/13/2024 | Inventor(s): Shashankkumar Patel, Nicholas Restifo

Keywords(s): CRISPR, diagnostic, Gene, Immunotherapy, T-cell, tumor

Category(s): Application > Diagnostics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Potassium Hydroxy Citrate Promotes Longevity and Efficacy of Anti-Tumor T cells for Adoptive Cell Therapy (ACT)

Abstract: Adoptive cell therapy (ACT) using tumor-specific T cells can produce positive clinical responses in some cancer patients. Nevertheless, several obstacles to the successful use of ACT for the treatment of cancer and other conditions remain. For example, one or more of the in vivo persistence, survival, and antitumor activity of tumor-specific...

Published: 4/8/2024 | Inventor(s): Suman Vodnala, Nicholas Restifo, Rigel Kishton, Robert Eil

Keywords(s): act, adoptive cell therapy, Memory T Cells, Potassium Hydroxy Citrate, Restifo, Vodnala

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Calcium (Ca2+) Flux-Dependent Method to Detect and Isolate Tumor Reactive T Cell Receptors (TCRs)

Abstract: T cells with T cell receptors (TCRs) for cancer-specific antigens are used for adoptive cell therapy (ACT), wherein a patient’s T cells are redirected against their own cancer. However, these isolated T cells may require further ex vivo manipulation to enhance their anti-tumor activity. The ex vivo manipulation of these T cells, or the selection...

Published: 4/8/2024 | Inventor(s): Douglas Palmer, Anna Pasetto, Nicholas Restifo, Steven Rosenberg

Keywords(s): act, Adoptive Cell Transfer, CA2+, Calcium Ion, Immunotherapy, Rosenberg, T Cell Receptor, TCR, tumor

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Cancer Therapeutic Based on T Cell Receptors Designed to Regiospecifically Release Interleukin-12

Abstract: Adoptive immunotherapy is a promising new approach to cancer treatment that engineers an individual''s innate and adaptive immune system to fight against specific diseases, including cancer with fewer side-effects and more specific anti-tumor activity in individual patients. T cell receptors (TCRs) and Chimeric Antigen Receptors (CARs) are...

Published: 4/8/2024 | Inventor(s): Richard Morgan, Nicholas Restifo, Steven Rosenberg, Ling Zhang

Keywords(s): CARS, chimeric antigen receptor, human interleukin 12, IL-12, T Cell Receptor, TCRs

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Oncology

1 2